BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sets New 12-Month Low – What’s Next?

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT)’s share price reached a new 52-week low on Thursday . The stock traded as low as $6.30 and last traded at $6.76, with a volume of 1498632 shares changing hands. The stock had previously closed at $8.86.

Analysts Set New Price Targets

Several equities analysts have recently commented on BBOT shares. Raymond James Financial decreased their target price on BridgeBio Oncology Therapeutics from $24.00 to $22.00 and set an “outperform” rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. dropped their price target on BridgeBio Oncology Therapeutics from $27.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research note on Thursday, June 18th. Wedbush reiterated an “outperform” rating and set a $25.00 price objective on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday. Finally, Canaccord Genuity Group dropped their target price on BridgeBio Oncology Therapeutics from $23.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.57.

BridgeBio Oncology Therapeutics Price Performance

The company has a market capitalization of $541.95 million, a price-to-earnings ratio of -2.45 and a beta of 0.38. The business’s 50-day moving average price is $8.77 and its two-hundred day moving average price is $8.73.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($705.20) EPS for the quarter. As a group, research analysts predict that BridgeBio Oncology Therapeutics, Inc will post -2.79 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BBOT. Granahan Investment Management LLC bought a new position in BridgeBio Oncology Therapeutics in the 1st quarter valued at about $2,068,000. Catalio Capital Management LP bought a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at $5,142,000. Armistice Capital LLC increased its stake in shares of BridgeBio Oncology Therapeutics by 142.7% in the 4th quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock valued at $12,520,000 after purchasing an additional 588,000 shares during the last quarter. BIT Capital GmbH acquired a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth $313,000. Finally, Tidal Investments LLC lifted its position in shares of BridgeBio Oncology Therapeutics by 13.6% during the 2nd quarter. Tidal Investments LLC now owns 93,339 shares of the company’s stock worth $711,000 after buying an additional 11,167 shares during the last quarter. Institutional investors and hedge funds own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.